6ER-014 Patient-reported outcomes regarding adalimumab new formulation

BackgroundAdalimumab is currently available in a 40 mg/0.4 mL formulation with fewer excipients, smaller volume and gauge needle, versus 40 mg/0.8 mL previous formulation.PurposeTo evaluate injection site-related pain (ISRP) and satisfaction of new adalimumab formulation in comparison with the previ...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of hospital pharmacy. Science and practice 2018-03, Vol.25 (Suppl 1), p.A236-A236
Hauptverfasser:	Sánchez, P López, Sacristán, A García, Morago, R Martínez, Cañas, AV Becerra, Nieves, JJ Márquez, Casanueva, T Sánchez, Sesmero, JM Martínez
Format:	Artikel
Sprache:	eng
Schlagworte:	Abdomen Arthritis Immunotherapy Monoclonal antibodies Section 6: Education and research TNF inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!